Stock Events

YiChang HEC ChangJiang Pharmaceutical 

HK$9.17
3
+HK$0.02+0.22% Friday 08:08

Statistics

Day High
9.27
Day Low
9.07
52W High
13.3
52W Low
6.02
Volume
402,000
Avg. Volume
1,879,291
Mkt Cap
6.84B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

23
AUG
Earnings

Dividends

0%Dividend Yield
Nov 20
HK$0.11
Jul 20
HK$0.33
Nov 19
HK$1.11
Jul 19
HK$0.68
Nov 18
HK$0.45
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

23AugConfirmed
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Next
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1558.HK. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BeiGene
BGNE
Mkt Cap15B
BeiGene is a biotechnology company in China focusing on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer, directly competing in the same therapeutic areas as YiChang HEC.
Zai Lab Limited
ZLAB
Mkt Cap1.86B
Zai Lab Limited is a Shanghai-based innovative biopharmaceutical company that develops and commercializes therapies in oncology and autoimmune diseases, overlapping with YiChang HEC's focus areas.
HUTCHMED (China) Limited
HCM
Mkt Cap3.3B
Hutchison China MediTech Limited, known as Chi-Med, is a biopharmaceutical company that develops therapies for oncology and immunological diseases, competing in similar markets as YiChang HEC.
Sinovac Biotech
SVA
Mkt Cap644.66M
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases, competing in the broader pharmaceutical field.
FibroGen
FGEN
Mkt Cap104.45M
FibroGen Inc is a biopharmaceutical company discovering, developing, and commercializing a pipeline of first-in-class therapeutics, and has operations in China, competing in the same sector.
Can-Fite Biopharma
CANF
Mkt Cap6.94M
Can-Fite BioPharma Ltd. is an advanced clinical stage drug development company with several drugs in the pipeline that could compete with YiChang HEC's products.
CASI Pharmaceuticals
CASI
Mkt Cap85.1M
CASI Pharmaceuticals is focused on acquiring, developing, and commercializing innovative therapeutics and pharmaceutical products, mainly in China, directly competing with YiChang HEC.
GSK
GSK
Mkt Cap81.55B
GlaxoSmithKline plc, a leading global pharmaceutical company, has a strong presence in China and competes across various therapeutic areas including those targeted by YiChang HEC.
Novartis
NVS
Mkt Cap232.42B
Novartis AG is a global healthcare company based in Switzerland that operates in similar therapeutic areas as YiChang HEC, making it a direct competitor in the global market.
Pfizer
PFE
Mkt Cap169.83B
Pfizer Inc. is one of the world's largest pharmaceutical companies, with a significant presence in China and competing across various drug categories, including those pursued by YiChang HEC.

About

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, and cardiovascular diseases in the People's Republic of China. It also manufactures and sells active pharmaceutical ingredients; researches and develops medical devices and drugs, as well as biotechnology; and provides medical consulting services. The company sells its products to hospitals and medical institutions through a network of distributors. It has a strategic cooperation framework agreement with Alibaba Health Technology (China) Limited to carry out influenza special projects; Jointown Pharmaceutical Group Co., Ltd.; Guangdong Yihao Pharmaceutical Co., Ltd.; and Shenzhen HEC Industrial Development Co., Ltd, as well as strategic cooperative partnership with China National Accord Medicines Corporation Ltd. The company was formerly known as Yichang Changjiang Pharmaceutical Company Limited and changed its name to YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in May 2015. The company was incorporated in 2001 and is based in Yichang, China. YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a subsidiary of Guangdong HEC Technology Holding Co., Ltd.
Show more...
CEO
Mr. Juncai Jiang
Employees
3919
Country
Hong Kong
ISIN
CNE1000023R6

Listings

HK
HK
1558.HK
OTCM
US
YIHCF